52980-10-6

Usage

Uses

Used in Pharmaceutical Industry:
2-Quinolinecarboxylicacid,6-amino-1,4-dihydro-4-oxo-(9CI) is used as a synthetic intermediate for the development of pharmaceuticals. Its unique structure allows for the creation of new compounds with potential therapeutic applications, making it a valuable asset in the discovery and production of novel medications.
Used in Chemical Industry:
In the chemical industry, 2-Quinolinecarboxylicacid,6-amino-1,4-dihydro-4-oxo-(9CI) serves as a key component in the synthesis of various organic compounds. Its presence in these compounds can contribute to their chemical properties and potential uses, expanding the range of applications for this versatile molecule.

Upstream product

• 52144-24-8 4-hydroxy-6-nitro-quinoline-2-carboxylic acid ethyl ester 
• 16133-44-1 dimethyl 2-<(4-nitrophenyl)amino>-2-butenedioate 
• 100-01-6 4-nitro-aniline 
• 16133-46-3 methyl 1,4-dihydro-6-nitro-4-oxo-2-quinolinecarboxylate 
• 52979-42-7 methyl 6-amino-1,4-dihydro-4-oxo-2-quinolinecarboxylate 
• 52979-42-7 6-amino-4-hydroxy-2-methoxycarbonylquinoline 
• 24782-43-2 ethyl 4-hydroxyquinoline-2-carboxylate 
• 859982-04-0 6-acetylamino-4-hydroxy-quinoline-2-carboxylic acid ethyl ester 

Downstream Products

• 56717-02-3 6-amino-quinolin-4-ol 
• 874497-95-7 N-(4-amino-[6]quinolyl)-acetamide 
• 40107-09-3 4,5-Diamino-chinolin 

Relevant academic research and scientific papers

ANTIBODIES AGAINST SEROTONIN, TRYPTOPHAN AND KYNURENINE METABOLITES AND USES THEREOF

The present invention provides antibodies and methods for preparing antibodies to metabolites in the serotonin, tryptophan and kynurenine pathways, such as 5- hydroxyindole-3-acetic acid (5-HIAA), melatonin (MT) and kynurenic acid (KYNA). The specific metabolite antibodies have low cross-reactivity to structurally related metabolites, and are useful reagents for specific and sensitive immunoassays. The present invention also provides methods for using such antibodies to measure the levels of 5-HIAA, melatonin, or kynurenic acid in biological samples from human patients.

PATHWAY SPECIFIC ASSAYS FOR PREDICTING IRRITABLE BOWEL SYNDROME DIAGNOSIS

The present invention provides antibodies and methods for preparing antibodies to metabolites in the serotonin, tryptophan, kynurenine pathways. The prepared antibodies have low cross-reactivity to related metabolites, and are useful reagents for specific and sensitive immunoassays The present invention also provides stable derivatives of various metabolites and short chain fatty acids. The derivative can be conjugated to a biomolecule such as a carrier protein and combined with an adjuvant to stimulate an immune response. The derivatives can also be conjugated to other biomolecules.

2-AMINOCARBONYL-QUINOLINE COMPOUNDS AS PLATELET ADENOSINE DIPHOSPHATE RECEPTOR ANTAGONISTS

Compounds of formula (I), where m, n, R1, R2, R3, R4 and R6 are described herein, are useful as inhibitors of platelet adenosine diphosphate. Pharmaceutical compositions containing these compounds, methods of using these compounds as antithrombotic agents and processes for synthesizing these compounds are also described herein.

Platelet adenosine diphosphate receptor antagonists

Compounds of the following formula (I): where a, b, R1, R2, R4 and R6 are described herein, are useful as inhibitors of platelet adenosine diphosphate. Pharmaceutical compositions containing these compounds, met

Kynurenic acid derivatives inhibit the binding of nerve growth factor (NGF) to the low-affinity p75 NGF receptor

The ability of a series of substituted kynurenic acids, thienopyridinonecarboxylic acids, and related compounds to inhibit the binding of nerve growth factor (NGF) to the p75 NGF receptor (NGFR) was evaluated in a radioligand binding assay that utilized a